Dept. of Organon of Medicine and Homoeopathic Philosophy, D. N. De Homoeopathic Medical College and Hospital, Govt. of West Bengal, 12, Gobinda Khatick Road, Kolkata 700046, West Bengal, India.
Dept. of Organon of Medicine and Homoeopathic Philosophy, D. N. De Homoeopathic Medical College and Hospital, Govt. of West Bengal, 12, Gobinda Khatick Road, Tangra, Kolkata 700046, West Bengal, India.
Explore (NY). 2024 Sep-Oct;20(5):102995. doi: 10.1016/j.explore.2024.03.003. Epub 2024 Apr 4.
Pre-diabetes is a significant public health problem worldwide. India has a very high rate of progression from pre-diabetes to diabetes, 75-78 per thousand persons per year.
To study the efficacy of individualized homeopathic medicinal products (HMPs) against placebos in preventing the progression from pre-diabetes to diabetes.
Six-month, double-blind, randomized (1:1), two parallel arms, placebo-controlled trial.
Outpatient departments of D. N. De Homoeopathic Medical College and Hospital, Kolkata, West Bengal, India.
Sixty participants with pre-diabetes.
Verum: HMPs plus yoga therapy (YT; n = 30); control: identical-looking placebos plus YT (n = 30).
The primary efficacy endpoint was the proportion of participants progressing from pre-diabetes to diabetes, measured after three and six months. Secondary outcomes comprised of fasting blood glucose (FBS), oral glucose tolerance test (OGTT), glycated hemoglobin percentage (HbA1c%), lipid profile, liver enzymes (alanine transaminase, aspartate transaminase), urea and creatinine, and Measure Yourself Medical Outcome Profile version 2 (MYMOP-2); all measured after 3 and 6 months.
The proportion of participants converted from pre-diabetics to diabetics (n/N; n = diabetics, N = prediabetics) was significantly less in the verum group than control: HbA1C% (month 3: verum - 2/30 versus control - 11/30, p = 0.003; month 6: 3/30 vs. 2/30, p = 0.008), OGTT (month 3: 0/30 vs. 8/30, p = 0.015; month 6: 0/30 vs. 1/30, p = 0.008), but not according to FBS (month 3: 1/30 vs. 1/30, p = 0.779; month 6: 1/30 vs. 3/30, p = 0.469). Several secondary outcomes also revealed significant improvements in the verum group than in placebo: HbA1C% (p < 0.001), OGTT (p = 0.001), serum ALT (p = 0.031), creatinine (p = 0.012), and MYMOP-2 profile scores (p < 0.001). Sulphur, Bryonia alba, and Thuja occidentalis were the most frequently indicated medicines. Thus, HMPs outperformed placebos by successfully preventing the progression of pre-diabetes to diabetes.
Clinical Trials Registry - India CTRI/2022/04/042,026; UTN: U1111-1277-0021.
糖尿病前期是全球一个重大的公共卫生问题。印度有非常高的从糖尿病前期发展为糖尿病的比例,每年每千人中有 75-78 人。
研究个体化顺势疗法药物(HMPs)在预防糖尿病前期进展为糖尿病方面相对于安慰剂的疗效。
为期 6 个月的、双盲、随机(1:1)、两平行臂、安慰剂对照试验。
印度西孟加拉邦加尔各答 D. N. De Homoeopathic 医学院和医院的门诊部门。
60 名患有糖尿病前期的参与者。
阳性药物:HMPs 加瑜伽疗法(YT;n=30);对照:外观相同的安慰剂加 YT(n=30)。
主要疗效终点是参与者从糖尿病前期发展为糖尿病的比例,在 3 个月和 6 个月后进行测量。次要结局包括空腹血糖(FBS)、口服葡萄糖耐量试验(OGTT)、糖化血红蛋白百分比(HbA1c%)、血脂谱、肝酶(丙氨酸转氨酶、天冬氨酸转氨酶)、尿素和肌酐以及自我评估医疗结局测量 2 版(MYMOP-2);所有这些指标均在 3 个月和 6 个月后进行测量。
阳性组中从糖尿病前期患者转变为糖尿病患者的比例(n/N;n=糖尿病患者,N=糖尿病前期患者)明显低于对照组:HbA1C%(第 3 个月:阳性组-2/30 与对照组-11/30,p=0.003;第 6 个月:3/30 与 2/30,p=0.008)、OGTT(第 3 个月:0/30 与 8/30,p=0.015;第 6 个月:0/30 与 1/30,p=0.008),但 FBS 则不然(第 3 个月:1/30 与 1/30,p=0.779;第 6 个月:1/30 与 3/30,p=0.469)。阳性组的多项次要结局也明显优于安慰剂组:HbA1C%(p<0.001)、OGTT(p=0.001)、血清 ALT(p=0.031)、肌酐(p=0.012)和 MYMOP-2 评分(p<0.001)。硫磺、白屈菜和泽兰是最常被指示的药物。因此,HMPs 成功地预防了糖尿病前期向糖尿病的进展,优于安慰剂。
临床试验注册印度 CTRI/2022/04/042,026;UTN:U1111-1277-0021。